Firebrick Pharma First Half 2025 Earnings: AU$0.007 loss per share (vs AU$0.005 loss in 1H 2024)
Firebrick Pharma (ASX:FRE) First Half 2025 Results
Key Financial Results
- Revenue: AU$197.1k (down 89% from 1H 2024).
- Net loss: AU$1.45m (loss widened by 61% from 1H 2024).
- AU$0.007 loss per share (further deteriorated from AU$0.005 loss in 1H 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Firebrick Pharma shares are up 1.2% from a week ago.
Risk Analysis
Be aware that Firebrick Pharma is showing 5 warning signs in our investment analysis and 3 of those make us uncomfortable...
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.
Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10